Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Regeneron and P&G joint development program for obesity

Oct. 3, 1997

L-Arginine not associated with objective improvement in organic ED

Oct. 3, 1997

Linsidomine + moxisylyte for ED

Oct. 3, 1997

Effects of BQ-123 and BQ-788 on ET-1-induced corpus cavernosum contractions

Oct. 3, 1997

Intracavernous moxisylyte recommended for first-line treatment of ED

Oct. 3, 1997

BioTime completes phase III trial with blood volume plasma extender

Oct. 3, 1997

First registration filing for Unigene's injectable calcitonin product

Oct. 2, 1997

Quinacrine sterilization reviewed

Oct. 2, 1997

New agents for NIDDM presented by Pharmacia & Upjohn

Oct. 1, 1997

Pfizer seeks U.S. and European approval for Viagra

Sep. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...